ATI 1645
Alternative Names: ATI-1645Latest Information Update: 03 Jan 2023
At a glance
- Originator IRBM; National Institute of Molecular Genetics; Ospedale San Raffaele; Promidis
- Class Antivirals; Hepatoprotectants
- Mechanism of Action Capsid protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hepatitis B
Most Recent Events
- 04 Nov 2022 Pharmacodynamics data from preclinical studies in Hepatitis B presented at 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2022)
- 01 Jul 2022 Antios Therapeutics plans a clinical trial for Hepatitis B in mid-2023
- 28 Jun 2022 Early pharmacodynamics data from a preclinical trial in Hepatitis B presented at the European Association for the Study of the Liver's International Liver Congress 2022 (EASL ILC 2022)